Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | BAY1834942 |
Synonyms | |
Therapy Description |
BAY1834942 (tinurilimab) is a monoclonal antibody against CEACAM6 that blocks downstream signaling, resulting in enhanced T-cell response (Cancer Res 2018;78(13 Suppl):Abstract nr 1771). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
BAY1834942 | BAY-1834942|BAY 1834942|tinurilimab | CEACAM6 Antibody 3 | BAY1834942 (tinurilimab) is a monoclonal antibody against CEACAM6 that blocks downstream signaling, resulting in enhanced T-cell response (Cancer Res 2018;78(13 Suppl):Abstract nr 1771). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03596372 | Phase I | BAY1834942 | Study of BAY1834942 in Patients With Solid Tumors | Completed | USA | CAN | 1 |